抗血小板药物新进展

随着我国人口老龄化，动脉粥样硬化血栓形成疾病的发生率日益增加，口服抗血小板治疗，如环氧化酶-1受体抑制剂阿司匹林和噻吩并吡啶P2Y12受体拮抗剂氯吡格雷是最为常用的药物。但它们在有效性，患者耐受性，对血小板抑制作用的可逆性，以及不同患者对药物反应的差异性等方面都有一定不足。目前一些新的抗血小板药物正在进入最后研究阶段，初步结果显示其作用更强，与传统药物相比更加安全和方便。现对常用口服抗血小板药物的局限性及正在研究中的一些新药物做一综述。

New Developments in Antiplatelet Agents

As a result of the aging Chinese population, the incidence of atherosclerotic thrombotic diseases have increased. Oral antiplatelet therapy, such as cycloxygenase-1 receptor inhibiter aspirin, or thienopyridine P2Y12 receptor antagonist clopidogrel are the most common agents used for treatment. There are, however, some limitations in their efficacy, tolerability, functional reversibility, and responsive variability. Nowadays some new antiplatelet agents have been developed, and are in the final stages of testing. Initial results show that they can offer improved efficacy, safety, and convenience. This article reviews the limitations of traditional antiplatelet agents, and introduces some of the new drugs which are undergoing clinical development.